3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
10
Stomach Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Esophageal Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Unresectable Locally Recurrent Breast Cancer
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm, Residual
1
Inflammatory Breast Neoplasms
1
HER2-negative Breast Cancer
1
HER2-mutant Non-Small Cell Lung Cancer
1
HER2-low Hormone Receptor Positive Breast Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Gastric Adenocarcinoma
1
Colonic Neoplasms
1
Interventions
Fluorouracil
87
Leucovorin
78
Oxaliplatin
77
Irinotecan
76
Bevacizumab
50
Cetuximab
42
Capecitabine
42
Panitumumab
17
Folfox protocol
16
Floxuridine
11
Chemotherapy, Adjuvant
11
regorafenib
10
IFL protocol
10
Nivolumab
9
Drug Therapy
9
trifluridine tipiracil drug combination
8
Surgical Procedures, Operative
8
Neoadjuvant Therapy
8
sargramostim
7
pembrolizumab
7
XELOX
7
Specimen Handling
7
Biopsy
7
Trastuzumab
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
HMPL-013
6
tislelizumab
5
encorafenib
5
Trifluridine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colonic Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07407465
2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
42 enrolled